ArticleBiophysics reports2020
Stimuli-responsive polymeric nanomaterials for rheumatoid arthritis therapy.
Article in Biophysics reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Antimicrobial nanomaterials at the nanoscale: design principles, mechanisms, and global challenges.Nanoscale advances · 2026Review
- Bridging Pharmacology and Nanotechnology: Mechanistic Insights into Traditional Chinese Medicine-Based Nanodelivery Systems for Rheumatoid Arthritis.International journal of nanomedicine · 2026Review
- Innovative nanocarriers in arthritis therapy: the role of herbal cubosomes.Inflammopharmacology · 2025Review
- Management of Rheumatoid Arthritis By Development of Nanocarriers and their Significance Over Conventional Dosage Forms.Recent advances in drug delivery and formulation · 2025Review
- Drug Targeting and Nanotherapeutic Advancement in the Treatment of Rheumatoid Arthritis: Recent Progress in Drug Delivery Systems.Current pharmaceutical biotechnology · 2025Review
- Multi-stimuli-responsive Hydrogels for Therapeutic Systems: An Overview on Emerging Materials, Devices, and Drugs.Current pharmaceutical design · 2024Review
- A Bird's Eye View of Various Cell-Based Biomimetic Nanomedicines for the Treatment of Arthritis.Pharmaceutics · 2023Review
- Fabrication of a Dual-Drug-Loaded Smart Niosome-g-Chitosan Polymeric Platform for Lung Cancer Treatment.Polymers · 2023Article
- Recent advances in nanoparticle-based drug delivery systems for rheumatoid arthritis treatment.Nanoscale advances · 2022Review
- Exploration of Site-Specific Drug Targeting-A Review on EPR-, Stimuli-, Chemical-, and Receptor-Based Approaches as Potential Drug Targeting Methods in Cancer Treatment.Journal of oncology · 2022Review
- Polymeric Micro/Nanocarriers and Motors for Cargo Transport and Phototriggered Delivery.Polymers · 2021Review
- Nanomaterials for the Diagnosis and Treatment of Inflammatory Arthritis.International journal of molecular sciences · 2021Review
- Stimuli-Responsive Nanoplatforms for Precision Intervention in Rheumatoid Arthritis.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a long-term inflammatory disease derived from an autoimmune disorder of the synovial membrane. Current therapeutic strategies for RA mainly aim to hamper the macrophages' proliferation and reduce the production of pro-inflammatory cytokines. Therefore, the accumulation of therapeutic agents targeted at the inflammatory site should be a crucial therapeutic strategy. Nowadays, the nanocarrier system incorporated with stimuli-responsive property is being intensively studied, showing the potentially tremendous value of specific therapy. Stimuli-responsive (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.